Greenwich LifeSciences does not distribute cash dividends to its common shareholders. As a pre-revenue, clinical-stage biotechnology enterprise, the company directs all available capital resources, cash reserves, and financing proceeds toward funding its expensive multi-country clinical trials, research pipelines, and corporate overhead expenses rather than offering dividend yields.